“Therepi” device attaches directly to damaged heart, enabling delivery of medicine from a port under a patient’s skin to augment cardiac function.
After a patient has a heart attack, a cascade of events leading to heart failure begins. Damage to the area in the heart where a blood vessel was blocked leads to scar tissue. In response to scarring, the heart will remodel to compensate. This process often ends in ventricular or valve failure.
A team of researchers is hoping to halt the progression from heart attack to heart failure with a small device called “Therepi.” The device contains a reservoir that attaches directly to the damaged heart tissue. A refill line connects the reservoir to a port on or under the patient’s skin where therapies can be injected either by the patient or a health care professional.
A new study published in Nature Biomedical Engineering involving a team of researchers from MIT, Harvard University, Royal College of Surgeons in Ireland, Trinity College Dublin, Advanced Materials and BioEngineering Research (AMBER) Center, and National University of Ireland Galway details how Therepi can be used to restore cardiac function.